Q-omics provides the consensus-scored NMNAT3 profile across patient tissues and cancer cell-line models. NMNAT3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NMNAT3 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, NMNAT3 RNA expression shows 20,092 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, THCA, and LSCC as cancer lineages where NMNAT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NMNAT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NMNAT3 survival associations across molecular data types. NMNAT3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NMNAT3 RNA expression–survival associations across cancer types. High NMNAT3 expression shows unfavorable associations in LGG and COAD, but favorable associations in UVM, KIRC, BRCA and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NMNAT3 RNA expression.
This table summarizes NMNAT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NMNAT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NMNAT3 shows lower tumor expression in THCA, LUAD, UCEC and KIRC and higher tumor expression in LUSC and COAD. The THCA box plot shows higher NMNAT3 RNA expression in normal versus tumor tissue (log2 FC = −1.627, t-test p < 0.001).
This table shows molecular features associated with NMNAT3 in patient tissues and cancer cell lines. In patient samples, NMNAT3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NMNAT3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
